OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Neurology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision	213
Cognitive decline among individuals with history of mild symptomatic SARS‐CoV‐2 infection: A longitudinal prospective study nested to a population cohort	123
Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study	119
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial	118
Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus‐2 infection: A systematic review and meta‐analysis	114
Encephalitis as a neurological complication of COVID‐19: A systematic review and meta‐analysis of incidence, outcomes, and predictors	113
Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity	104
Cytokine release syndrome‐associated encephalopathy in patients with COVID‐19	103
Headache as an acute and post‐COVID‐19 symptom in COVID‐19 survivors: A meta‐analysis of the current literature	96
COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response	96
Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series	87
Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis	86
Post‐SARS‐CoV‐2‐vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency	82
European Stroke Organisation and European Academy of Neurology joint guidelines on post‐stroke cognitive impairment	76
European guideline and expert statements on the management of narcolepsy in adults and children	74
Neuropathological findings from COVID‐19 patients with neurological symptoms argue against a direct brain invasion of SARS‐CoV‐2: A critical systematic review	73
Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study	67
One‐year cognitive follow‐up of COVID‐19 hospitalized patients	66
COVID‐19 and ischemic stroke	64
Myopathy as a cause of fatigue in long‐term post‐COVID‐19 symptoms: Evidence of skeletal muscle histopathology	62
Increased risk of acute stroke among patients with severe COVID‐19: a multicenter study and meta‐analysis	60
Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival	55
Altered motor cortex physiology and dysexecutive syndrome in patients with fatigue and cognitive difficulties after mild COVID‐19	54
Rapid onset of functional tic‐like behaviours in young adults during the COVID‐19 pandemic	53
Clinical characteristics and outcomes of thymoma‐associated myasthenia gravis	51

Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel	51
Functional motor disorders associated with other neurological diseases: Beyond the boundaries of “organic” neurology	50
Subthalamic beta band suppression reflects effective neuromodulation in chronic recordings	50
Minocycline in neurodegenerative and psychiatric diseases: An update	49
International online survey of 1048 individuals with functional neurological disorder	48
Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement	48
Blood–brain barrier leakage and hemorrhagic transformation: The Reperfusion Injury in Ischemic StroKe (RISK) study	48
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study	47
Distal hereditary motor neuropathies: Mutation spectrum and genotype–phenotype correlation	46
Myasthenia gravis associated with anti‐MuSK antibodies developed after SARS‐CoV‐2 infection	45
Headache during SARS‐CoV‐2 infection as an early symptom associated with a more benign course of disease: a case–control study	45
Unraveling the enigma of new‐onset refractory status epilepticus: a systematic review of aetiologies	45
COVID‐19 pandemic and mental distress in multiple sclerosis: Implications for clinical management	44
Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology	43
Cognitive sequelae of long COVID may not be permanent: A prospective study	43
Olfactory bulb and mucosa abnormalities in persistent COVID‐19‐induced anosmia: a magnetic resonance imaging study	41
Predictive factors of smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction	41